Multiple indications for everolimus after liver transplantation in current clinical practice

Table 6 Efficacy in cases of early (within one year post-transplantation) and late (after one year post-transplantation) conversion to everolimus n (%)

Early conversion
Cause of conversion	42 (56.8)	Resolution/stabilization or prevention of recurrence in 29 patients (69)
Refractory rejection	13 (17.6)	Resolution in 11 (84.6)
Advanced HCC in explanted liver	12 (16.3)	Prevention of recurrence in 6 (50)
HCC recurrence during follow-up	3 (4.1)	-
De novo tumour	0	-
CNI-related neurotoxicity	8 (10.8)	Resolution or amelioration in 8 (100)
Renal dysfunction	4 (5.4)	Resolution in 3 (75)
Other causes	2 (2.6)	Resolution in 1 (50)
Late conversion
Cause of conversion	32 (43.2)	Resolution/stabilization or prevention of recurrence in 16 patients (50)
Refractory rejection	10 (13.5)	Resolution in 6 (60)
Advanced HCC in ex planted liver	2 (2.7)	Prevention of recurrence in 1 (50)
HCC recurrence during follow-up	3 (4.1)	-
De novo tumour	13 (17.6)	Prevention of recurrence in 8 (61.5)
CNI-related neurotoxicity	0	-
Renal dysfunction	2 (2.7)	Resolution in none (0)
Other causes	2 (2.7)	Resolution in 1 (50)

HCC: Hepatocellular carcinoma; CNI: Calcineurine inhibitors.